COAG (Hemab Therapeutics Holdings) Institutional Ownership: 77.47% (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $44.73
! 1 Warning Sign
View Full Analysis

What is Hemab Therapeutics Holdings Institutional Ownership?

Hemab Therapeutics Holdings COAG +1.54% 11 Institutional Ownership is 77.47% as of Sep. 02, 2026. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hemab Therapeutics Holdings's institutional ownership is 77.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hemab Therapeutics Holdings's Insider Ownership is 0.08%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hemab Therapeutics Holdings's Float Percentage Of Total Shares Outstanding is 0.00%.

Hemab Therapeutics Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Institutional Ownership Chart

Hemab Therapeutics Holdings Historical Data

The historical data trend for Hemab Therapeutics Holdings can be seen below:

2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 9.96 20.46 21.58
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 77.47% mean?
Hemab Therapeutics Holdings (COAG) has a Institutional Ownership of 77.47% as of Sep. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Institutional Ownership too high?
Hemab Therapeutics Holdings' current Institutional Ownership is 77.47%. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Institutional Ownership compare to ADMA and VCEL?
Hemab Therapeutics Holdings' Institutional Ownership of 77.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Institutional Ownership is 77.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Institutional Ownership of 77.47%. The current Institutional Ownership is 77.47%. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Institutional Ownership is 77.47% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.73
Price